In order to enhance the clinical applicability of our findings, we transformed them into the measure of worsening risk per 1-nmol/L increment, yielding the following outcome: in MG patients with a baseline Lp(a) concentration range of 7.7–58 nmol/L, a 1-nmol/L increase in Lp(a) was correlated with a 95 % increased likelihood of worsening in MG within a 1-year period. This evidence concerns the gene LPA and myasthenia gravis.